Welcome to our dedicated page for Bioatla news (Ticker: BCAB), a resource for investors and traders seeking the latest updates and insights on Bioatla stock.
BioAtla, Inc. (BCAB) is a clinical-stage biopharmaceutical innovator advancing conditionally active biologic therapies for cancer treatment. This news hub provides investors and industry professionals with essential updates on the company’s proprietary CAB technology platform, clinical trial progress, and strategic developments.
Access timely press releases covering key milestones including regulatory filings, partnership announcements, and financial results. Our curated collection features updates on antibody-drug conjugate trials, intellectual property expansions, and operational developments across BioAtla’s global facilities.
This resource serves as your primary source for tracking BCAB’s progress in developing tumor-selective therapies. Bookmark this page for direct access to verified corporate communications and objective reporting on clinical advancements. Check regularly for updates on pipeline candidates and business strategy execution.
BioAtla (Nasdaq: BCAB), a global clinical-stage biotechnology company, has announced its upcoming participation in the Citizens Life Sciences Conference in New York. The company, which specializes in developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, will deliver a corporate update and engage in one-on-one investor meetings.
The presentation is scheduled for Wednesday, May 7, 2025, at 10:00 a.m. ET in New York. Company management will be available for individual investor discussions during the two-day conference, which runs from May 7-8, 2025. A webcast link has been provided for those interested in following the corporate update remotely.
BioAtla, a global clinical-stage biotechnology company, has scheduled its first quarter 2025 financial results announcement and business highlights conference call for May 6, 2025, at 4:30 p.m. ET.
The company, which specializes in developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, will host both a conference call and webcast. Investors and interested parties can access the event through:
- Domestic dial-in: (800) 245-3047
- International dial-in: (203) 518-9765
- Conference ID: BIOATLA
Financial results will be available before the conference call via the "News Releases" section on BioAtla's website. A replay of the presentation will be accessible through the "Events & Presentations" section in the Investors area of the company website.
BioAtla (BCAB) has announced two poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 25-30, 2025. The presentations will showcase the company's proprietary Conditionally Active Biologic (CAB) technology.
The first poster demonstrates CAB anti-Nectin4-antibody drug conjugate's superior efficacy compared to enfortumab vedotin analogue in multiple cancer models. The second presentation focuses on novel senolytic targets and CAB-based drug conjugates for targeting senescence-associated secretory phenotype cells.
The presentations will be held on April 27 and April 28, 2025, featuring research by authors including Jian Chen, Jing Wang, and others. The CAB technology aims to provide a new generation of biologics with improved safety margins and therapeutic index, specifically targeting acidic senescence in cancer and age-related diseases.
BioAtla (BCAB), a clinical-stage biotech company specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, has announced an upcoming poster presentation at the 2025 ASCO Annual Meeting. The event will be held both online and at Chicago's McCormick Place Convention Center from May 30–June 3, 2025.
The presentation will feature Phase 2 trial results of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in treating patients with heavily pretreated squamous cell carcinoma of the head and neck. The poster presentation (Abstract #6048, Poster #456) is scheduled for Monday, June 2, 2025, from 9:00 AM to 12:00 PM CDT during the Head and Neck Cancer session.
BioAtla (BCAB) reported its Q4 and full year 2024 financial results, highlighting progress in its clinical programs. The company's CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 study continues with data readout expected mid-2025.
Key highlights include mecbotamab vedotin showing exceptional overall survival in mKRAS NSCLC patients, with 66% one-year and 58% two-year survival rates. Ozuriftamab vedotin demonstrated 45% ORR in HPV-positive SCCHN patients.
Financial results show Q4 2024 R&D expenses of $11.6M (down from $22.7M in Q4 2023) and G&A expenses of $4.6M (down from $5.9M). Net loss was $14.9M compared to $26.9M in Q4 2023. The company ended 2024 with $49.0M in cash, implementing a 30% workforce reduction to extend runway beyond key clinical readouts in 1H 2026.
BioAtla (Nasdaq: BCAB), a global clinical-stage biotechnology company specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has announced two upcoming poster presentations at prestigious medical conferences.
The company will present at the European Lung Cancer Congress (ELCC) 2025 in Paris, France (March 26-29, 2025) and the Mayo Clinic Multidisciplinary Head and Neck Cancer Symposium 2025 in Scottsdale, Arizona (March 27-29, 2025). The presentation materials will be made available on BioAtla's website under the 'Publication' section following the conferences.
BioAtla (BCAB), a global clinical-stage biotechnology company specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has scheduled its Fourth Quarter and Full-Year 2024 financial results announcement for March 27, 2025.
The company will host a conference call and webcast at 4:30 p.m. ET to discuss financial performance and provide business updates. Interested parties can access the call through domestic (800-245-3047) or international (203-518-9765) dial-in numbers using the Conference ID: BIOATLA.
BioAtla (NASDAQ: BCAB) has announced a registered direct offering of 9,679,158 common stock shares, each accompanied by a warrant to purchase one share at $1.19. The combined offering price is $0.9520 per share and warrant. The warrants will be exercisable after six months and expire in 5.5 years.
The offering is expected to generate approximately $9.2 million in gross proceeds, closing around December 20, 2024. The funds will support research and development initiatives, including key clinical programs: BA3182 Phase 1 dose escalation data (2Q25) and Phase 2 expansion data (1H26), and mecbotamab vedotin Phase 2B data in mKRAS NSCLC (1H26). Tungsten Advisors acted as the sole placement agent.
FAQ
What is the current stock price of Bioatla (BCAB)?
What is the market cap of Bioatla (BCAB)?
